Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSABiotechnology
+$0.42 today
- Market cap
- $7.47B
- Beta
- 0.12
- P/E (TTM)
- 57.2
- EPS (TTM)
- $0.95
Volume 0.33M
Average 0.66M
KNSA Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Kiniksa Pharmaceuticals, Ltd.NASDAQ: KNSA
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of $40.9M rose 118.1% year over year, ahead of the +28.1% change in trailing-twelve-month research & development. Sequentially, it rose 48.9% from the prior quarter. Over 3 fiscal years it compounded at +13.9% a year.
Context
- Research & development amounted to 14.3% of revenue in FY2025, down 12.1 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +118.1% holds above the trailing-twelve-month pace of +28.1%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 96.85M USD
- Year-over-year change
- -13.2%
- 4-year CAGR
- -0.6%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 96.85M | -13.2% |
| FY2024 | 2024-12-31 | 111.62M | +46.7% |
| FY2023 | 2023-12-31 | 76.1M | +16.2% |
| FY2022 | 2022-12-31 | 65.49M | -34.0% |
| FY2021 | 2021-12-31 | 99.3M | — |
Research & Development vs competitors
How KNSA compares with its peers on the latest reported figures
- KNSA's LTM Jun 2026 research & development of $127.15M is the 7th highest of the 10 companies compared; the peer median is $153.74M.
- Its year-over-year change of +28.1% is the 6th highest of 10, against a peer median of +46.0%.
- Research & development amounts to 15.1% of revenue for KNSA, versus a peer median of 482.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $468.85M | +16.2% | +41.8% | 6608.2% | |
| LTM Aug 2026 | $331.95M | +10.2% | +18.6% | 47.3% | |
| LTM Sep 2026 | $259.72M | +46.3% | +43.1% | 287.0% | |
| LTM Jun 2026 | $175.6M | +66.9% | +70.5% | 9222.6% | |
ORKAOruka Therapeutics, Inc. | LTM Sep 2026 | $153.74M | +46.0% | +182.5% | — |
| LTM Mar 2026 | $128.65M | -23.4% | +15.3% | 55.4% | |
| LTM Jun 2026 | $127.15M | +28.1% | +13.9% | 15.1% | |
| LTM Mar 2026 | $104.71M | +22.1% | +23.1% | 28.3% | |
| LTM Mar 2026 | $56.72M | +60.6% | -12.2% | 677.9% | |
| LTM Mar 2026 | $55.01M | +74.4% | +17.0% | 93235.6% | |
| Peer median (excluding KNSA) | $153.74M | +46.0% | +23.1% | 482.4% | |
Competitors are the stored peer set for KNSA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 38.54M | 220.18M | 270.26M | 423.24M | 677.56M |
| Cost of Revenue | 9.1M | 22.9M | 56.52M | 60.91M | 307.41M |
| Gross Profit | 29.44M | 197.29M | 213.74M | 362.33M | 370.15M |
| Gross Margin | 76.4% | 89.6% | 79.1% | 85.6% | 54.6% |
| Research & Development | 99.3M | 65.49M | 76.1M | 111.62M | 96.85M |
| Selling, General & Admin | 85.95M | 97.95M | 129.43M | 168.01M | 196.27M |
| Operating Expenses | 186.08M | 187.51M | 238.93M | 407.95M | 292.93M |
| Depreciation & Amortization | 2.36M | 2.4M | 2.34M | 1.7M | 1.55M |
| EBITDA | (154.18M) | 13.43M | (14.31M) | (34.46M) | 90.42M |
| EBITDA Margin | -400.0% | 6.1% | -5.3% | -8.1% | 13.3% |
| Operating Income | (156.64M) | 9.77M | (25.2M) | (45.62M) | 77.22M |
| Operating Margin | -406.4% | 4.4% | -9.3% | -10.8% | 11.4% |
| Interest Income | 97K | 1.25M | 8.54M | 9.46M | 11.65M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 97K | 1.25M | 8.54M | 9.46M | 11.65M |
| Income Before Tax | (156.54M) | 11.03M | (16.65M) | (36.15M) | 88.87M |
| Pre-Tax Margin | -406.1% | 5.0% | -6.2% | -8.5% | 13.1% |
| Income Tax Expense | 1.39M | (172.34M) | (30.74M) | 7.04M | 29.86M |
| Net Income | (157.92M) | 183.36M | 14.08M | (43.19M) | 59.01M |
| Net Margin | -409.7% | 83.3% | 5.2% | -10.2% | 8.7% |
| EPS (Basic) | (2.30) | 2.64 | 0.20 | (0.60) | 0.80 |
| EPS (Diluted) | (2.30) | 2.60 | 0.20 | (0.60) | 0.75 |
| Weighted Avg Shares | 68.58M | 69.38M | 70.06M | 71.42M | 74.2M |
| Weighted Avg Shares (Diluted) | 68.58M | 70.42M | 71.92M | 71.42M | 78.98M |
Kiniksa Pharmaceuticals, Ltd.
NASDAQ:KNSA
Intrinsic Alpha fair value
Locked
Current Price
$95.05
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.